Evaluation of Local Tumor Outcomes Following Microwave Ablation of Colorectal Liver Metastases Using CT Imaging: A Comparison of Visual versus Quantitative Methods.

Purpose To compare visual versus quantitative ablation confirmation for identifying local tumor progression and residual tumor following microwave ablation (MWA) of colorectal liver metastases (CRLM). Materials and Methods This retrospective study included patients undergoing MWA of CRLM from October 2014 to February 2018. Two independent readers visually assessed pre- and postprocedure images and semiquantitatively scored for incomplete ablation, using a six-point Likert scale, and extracted quantitative imaging metrics of minimal ablative margin (MAM) and percentage of tumor outside of the ablation zone, using both rigid and deformable registration.

Four-dimensional computed tomography as first-line imaging in primary hyperparathyroidism, a retrospective comparison to conventional imaging in a predominantly single adenoma population.

Background: To determine the use of four-dimensional CT as first-line imaging compared to the traditional combination of ultrasound and [Tc]Tc-Sestamibi SPECT.

Materials And Methods: Retrospective review of preoperative imaging in patients with primary hyperparathyroidism, who underwent parathyroidectomy between 2012 and 2021. In one group, the combination ultrasound and [Tc]Tc-Sestamibi SPECT was used as first-line imaging (n = 54), in the other group four-dimensional CT was the first-line imaging modality (n = 51).

The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.

Imaging before Ra-dichloride (Ra) therapy is crucial for selecting metastatic castration-resistant prostate cancer (mCRPC) patients with bone-only disease. The purpose of this study was to evaluate if baseline prostate-specific membrane antigen (PSMA) PET/CT (bPSMA) versus CT is associated with outcomes of Ra therapy. A secondary analysis of the data of a prospective observational study (NCT04995614) was performed.

Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).

Efficacy of the human epidermal growth factor receptor (HER)2-targeting trastuzumab emtansine (T-DM1) in breast cancer (BC) relies on HER2 status determined by immunohistochemistry or fluorescence in-situ hybridization. Heterogeneity in HER2 expression, however, generates interest in "whole-body" assessment of HER2 status using molecular imaging. We evaluated the role of HER2-targeted molecular imaging in detecting HER2-positive BC lesions and patients unlikely to respond to T-DM1.